Shares of the Creative Medical Technology Holdings, Inc. (CELZ) stock were soaring in the current market trading session today on January 3, 2022. CELZ stock price saw an uptrend of 40.27% to reach $3.10 a share at the time of this writing. The trading volume was 37,224,151 on the last check, far higher than the average trading volume.
Creative Medical Technology Holdings, Inc is a biotech company that is engaged in the development of urology, orthopedics, and neurology using adult stem cell treatments. CELZ stock has a market cap of $21.38 million market cap and a 725,863 average trading volume. Let’s deep dive to understand the reason behind the current rally.
What’s Happening?
CELZ has captivated the attention of investors in the stock market today. However, there is no stock-specific news to support the bullish sentiment. there is no press release or any announcement by the company to back the current positive momentum. No analyst has upgraded or increased per share target price of CELZ stock in recent times. From the social media analysis, it seems that this stock is hot among investors in the social media platforms like Reddit, Stock Twits, Twitter, etc. The discussions among investors are driving the per-share price of CELZ stock in today’s current market. For your intuition, lets discuss some recent events of Creative Medical Technology Holdings.
Report of ImmCelz™ Immunotherapy Product:
On October 12, 2021, the company reported proof of concept that demonstrated ImmCelz™ immunotherapy product’ ability to “reprogram” immune cells of the patient via “ex vivo cell-free” reprogramming protocol.” The company performed the study at the University of Miami, Miami FL. The Cure Alliance, a non-profit research organization supported the study.
ImmCelz™ provides the specific characteristics of the immune cells of the patient. For this purpose, it uses adult stem cells of qualified donors. After the incubation of immune cells with the company’s reprogramming cocktail, the immune cells are extracted and again injected into patients. Thus, these cells educate other cells to resist the foreign pathogens that can cause cancer.
Conclusion:
Things are going well for CELZ stock despite the absence of any stock-specific news. It would be interesting to see how long this trend will remain as the stock market is highly unpredictable. It is better to do fundamental as well as technical analysis before making any decision.
